Lipopeptide adjuvants in combination treatment

被引：12

作者：

Bessler, WG ^{[1
]}

Mittenbühler, K ^{[1
]}

Von der Esche, U ^{[1
]}

Huber, M ^{[1
]}

机构：

[1] Univ Freiburg Klinikum, AK Tumorimmunol Vakzine, Inst Mol Med & Zellforsch, D-79104 Fribourg, Switzerland

来源：

INTERNATIONAL IMMUNOPHARMACOLOGY | 2003年 / 3卷 / 08期

关键词：

lipopeptide; adjuvanticity; combination treatment;

D O I：

10.1016/S1567-5769(03)00027-4

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Synthetic lipopeptides derived from the N-terminus of bacterial lipoprotein constitute potent immunoadjuvants for parenteral and mucosal immunization. When combined with tetanus toxoid (TT) or gliadin as antigens, the lipopeptide N-palmitoyl-S-[2,3bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteinyl-seryl-(lysyl)(3)-lysine (P3CSK4) markedly enhanced the specific antibody levels. Lipopeptides also act as macrophage/monocyte activators: P3CSK4 induced nitric oxide release from bone marrow-derived macrophages (BMDM) of LPS responder and nonresponder mice. The antitumoral effect of the lipopeptide was demonstrated by a strong cytostatic activity of the lipopeptide-treated macrophages against the murine B-cell lymphoma cell line Abelson 8-1. The chemically well-defined lipopeptides can be synthesized with high purity and reproducibility and constitute ideal agents to be combined with antigens/vaccines or antitumor treatment. (C) 2003 Elsevier Science B.V. All rights reserved.

引用

页码：1217 / 1224

页数：8

共 22 条

[1] Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2 [J].

Aliprantis, AO ;

Yang, RB ;

Mark, MR ;

Suggett, S ;

Devaux, B ;

Radolf, JD ;

Klimpel, GR ;

Godowski, P ;

Zychlinsky, A .

SCIENCE, 1999, 285 (5428) :736-739

[2] Lipopeptides as immunoadjuvants and immunostimulants in mucosal immunization [J].

Baier, W ;

Masihi, N ;

Huber, M ;

Hoffmann, P ;

Bessler, WG .

IMMUNOBIOLOGY, 2000, 201 (3-4) :391-405

[3] Generation of antibodies directed against the low-immunogenic peptide-toxins microcystin-LR/RR and nodularin [J].

Baier, W ;

Loleit, M ;

Fischer, B ;

Jung, G ;

Neumann, U ;

Weiss, M ;

Weckesser, J ;

Hoffmann, P ;

Bessler, WG ;

Mittenbühler, K .

INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 2000, 22 (05) :339-353

[4]

Bessler W G, 1997, Behring Inst Mitt, P390

[5] SYNTHETIC LIPOPEPTIDES AS NOVEL ADJUVANTS [J].

BESSLER, WG ;

JUNG, G .

RESEARCH IN IMMUNOLOGY, 1992, 143 (05) :548-553

[6]

BOLTZ T, 1998, LYMPHOCYTE ACTIVATIO, P379

[7] INVIVO PRIMING OF VIRUS-SPECIFIC CYTO-TOXIC LYMPHOCYTES-T WITH SYNTHETIC LIPOPEPTIDE VACCINE [J].

DERES, K ;

SCHILD, H ;

WIESMULLER, KH ;

JUNG, G ;

RAMMENSEE, HG .

NATURE, 1989, 342 (6249) :561-564

[8]

DING AH, 1988, J IMMUNOL, V141, P2407

[9]

Gampp TM, 2001, EUR J MED RES, V6, P10

[10] ACTIVATION OF BONE MARROW-DERIVED MOUSE MACROPHAGES BY BACTERIAL LIPOPEPTIDE - CYTOKINE PRODUCTION, PHAGOCYTOSIS AND IA EXPRESSION [J].

HAUSCHILDT, S ;

HOFFMANN, P ;

BEUSCHER, HU ;

DUFHUES, G ;

HEINRICH, P ;

WIESMULLER, KH ;

JUNG, G ;

BESSLER, WG .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1990, 20 (01) :63-68

← 1 2 3 →